Breaking News Instant updates and real-time market news.

CEMP

Cempra

$22.59

-0.52 (-2.25%)

16:24
10/04/16
10/04
16:24
10/04/16
16:24

Cempra presents analysis showing rates of failure for existing CABP antibiotics

Cempra announced the presentation of three abstracts based upon analyzing treatment failures with existing antibiotics from more than 400,000 records of patients diagnosed with community-acquired bacterial pneumonia, CABP, in a large U.S. insurance claims database. The data analysis will be presented at the annual Academy of Managed Care Pharmacy Nexus meeting in National Harbor, MD from October 3-6, 2016. These patient records were analyzed to assess rates of failure to the most commonly prescribed antibiotics to treat CABP. Treatment failure was defined as antibiotic prescription refill, new antibiotic claim, emergency room visit, or hospitalization occurring within 30 days of initial therapy. This analysis showed that more than one out of five adult CABP patients failed initial antibiotic monotherapy, with the failure rate exceeding one out of four for an elderly population with certain comorbidities. In a separate analysis of the same database, an association was observed between macrolide-resistant S. pneumoniae, the most common cause of CABP, and macrolide treatment failure by region in the U.S., with the frequency of macrolide-resistant S. pneumoniae as high as 64 percent in the West South Central region of the U.S. Nationwide, the average frequency of macrolide-resistant S. pneumoniae was approximately 49 percent. "These data, showing a high level of macrolide resistance and a high level of treatment failure with the most commonly used antibiotics in CABP, highlight the urgent need for new treatment options for CABP," said Prabhavathi Fernandes, Ph.D., president and chief executive officer of Cempra.

  • 04

    Nov

  • 27

    Dec

CEMP Cempra
$22.59

-0.52 (-2.25%)

06/24/16
NEED
06/24/16
NO CHANGE
Target $48
NEED
Buy
Needham expects 'moderate success' for Cempra Solithera
After attending the company's investor day, Needham analyst Alan Carr says that he expects Cempra to have moderate success in commercializing its Solithera independently, due to challenges for a biotech company in penetrating urgent and primary care. However, and despite believing that the commercial opportunity is probably larger in hands of Big Pharma, the analyst thinks the company's share price does not reflect what Cempra can accomplish independently. He reiterates a Buy rating and $48 price target on the shares.
06/24/16
06/24/16
NO CHANGE

Needham sees Brexit making EU drug reviews 'less efficient, more expensive'
Needham analyst including Alan Carr, Chad Messer, Danielle Brill and Esther Pang noted that if Article 50 is invoked following the Brexit vote, the European Medicines Agency will need to move out of its current base in London and the U.K. will need to create its own separate regulatory organization for drugs, concluding that Brexit will lead to a "less efficient, more expensive, and potentially lengthier regulatory process" for drug approval in the EU and the U.K. Among the companies that are currently in discussions with the EMA or have drugs under MAA review, Needham lists ACADIA (ACAD) Celator (CPXX), Cempra (CEMP), Gilead (GILD) Intercept (ICPT), Seattle Genetics (SGEN), Valeant (VRX) and Progenics (PGNX).
07/12/16
JPMS
07/12/16
INITIATION
Target $31
JPMS
Overweight
Cempra initiated with an Overweight at JPMorgan
JPMorgan analyst Jessica Fye started Cempra with an Overweight rating and $31 price target. The analyst sees a "high probability of Fast Track US approval" by year-end for Solithera, a new antibiotic for community acquired pneumonia in adults. The analyst believes current share levels offer an attractive entry point.
09/13/16
RAJA
09/13/16
INITIATION
Target $32
RAJA
Outperform
Cempra initiated with an Outperform at Raymond James
Raymond James analyst Christopher Raymond initiated Cempra with an Outperform and a $32 price target. He believes Cempra's lead antibiotic Solithera holds a unique value proposition, the efficacy of a macrolide with improved barrier to resistance and a more favorable safety profile over fluoroquinolones. Raymond's 2025 end-market revenue estimate of $904 million assumes solely CAP usage, leaving other opportunities as call options.

TODAY'S FREE FLY STORIES

TRMK

Trustmark

$32.97

0.14 (0.43%)

16:31
04/25/17
04/25
16:31
04/25/17
16:31
Earnings
Trustmark reports Q1 EPS 46c, consensus 41c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 26

    Apr

X

U.S. Steel

$31.11

-0.09 (-0.29%)

16:31
04/25/17
04/25
16:31
04/25/17
16:31
Hot Stocks
U.S. Steel drops over 15% in after-hours following earnings report »

U.S. Steel shares are…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

16:31
04/25/17
04/25
16:31
04/25/17
16:31
Options
Preliminary option volume of 19.4M today »

Preliminary option volume…

TXN

Texas Instruments

$82.37

1.29 (1.59%)

16:30
04/25/17
04/25
16:30
04/25/17
16:30
Earnings
Texas Instruments reports Q1 EPS 97c, consensus 83c »

Reports Q1 revenue $3.4B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 09

    May

  • 31

    May

CHSP

Chesapeake Lodging

$24.70

0.29 (1.19%)

16:29
04/25/17
04/25
16:29
04/25/17
16:29
Earnings
Chesapeake Lodging sees Q2 AFFO 60c-64c »

Sees Q2 EPS 27c-30c,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 17

    May

TGI

Triumph Group

$26.20

-0.05 (-0.19%)

16:29
04/25/17
04/25
16:29
04/25/17
16:29
Hot Stocks
Triumph Group, VAS Aero collaborate on PW4168 Nacelles »

Triumph Group said it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNPR

Juniper

$27.78

-0.49 (-1.73%)

16:28
04/25/17
04/25
16:28
04/25/17
16:28
Earnings
Juniper reports preliminary Q1 EPS 46c, consensus 42c »

Reports preliminary Q1…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 25

    May

  • 08

    Jun

CHSP

Chesapeake Lodging

$24.70

0.29 (1.19%)

16:28
04/25/17
04/25
16:28
04/25/17
16:28
Earnings
Chesapeake Lodging backs FY17 adjusted FFO $2.10-$2.20 »

Backs FY17 EPS 73c-83c,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 17

    May

ARCW

ARC Group

$3.85

0.05 (1.32%)

16:28
04/25/17
04/25
16:28
04/25/17
16:28
Hot Stocks
Breaking Hot Stocks news story on ARC Group »

Northern Right Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CHSP

Chesapeake Lodging

$24.70

0.29 (1.19%)

16:27
04/25/17
04/25
16:27
04/25/17
16:27
Earnings
Chesapeake Lodging reports Q1 adjusted FFO 41c »

Reports Q1 EPS 9c,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 17

    May

BXMT

Blackstone Mortgage

$30.91

0.28 (0.91%)

16:26
04/25/17
04/25
16:26
04/25/17
16:26
Earnings
Blackstone Mortgage reports Q1 core EPS 61c, consensus 63c »

Reports book value of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CCUR

Concurrent

$4.94

0.0626 (1.28%)

16:26
04/25/17
04/25
16:26
04/25/17
16:26
Hot Stocks
Concurrent announces availability of Origin Release 3 »

Concurrent announces the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UHS

Universal Health

$121.42

0.52 (0.43%)

16:25
04/25/17
04/25
16:25
04/25/17
16:25
Earnings
Universal Health reports Q1 adjusted EPS $2.10, consensus $2.07 »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 03

    May

PCG

PG&E

$67.66

-0.13 (-0.19%)

, EIX

Edison International

$80.82

-0.12 (-0.15%)

16:25
04/25/17
04/25
16:25
04/25/17
16:25
Hot Stocks
PG&E, CA energy companies propose reforms to CPUC »

PG&E (PCG) joined…

PCG

PG&E

$67.66

-0.13 (-0.19%)

EIX

Edison International

$80.82

-0.12 (-0.15%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 01

    May

  • 02

    May

DECK

Deckers Brands

$58.74

0.4 (0.69%)

16:25
04/25/17
04/25
16:25
04/25/17
16:25
Technical Analysis
Deckers Brands spikes after saying it will review strategic alternatives »

The stock was last at $62…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AVXS

AveXis

$78.74

-0.44 (-0.56%)

16:25
04/25/17
04/25
16:25
04/25/17
16:25
Conference/Events
AveXis to hold a conference call »

Management discusses the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 06

    Jun

TRN

Trinity Industries

16:24
04/25/17
04/25
16:24
04/25/17
16:24
Earnings
Trinity Industries sees 2017 EPS $1.00-$1.25 vs. prior outlook $1.00-$1.35 

Consensus $1.23.

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 01

    May

  • 09

    May

CHFC

Chemical Financial

$50.36

-0.35 (-0.69%)

16:24
04/25/17
04/25
16:24
04/25/17
16:24
Earnings
Chemical Financial reports Q1 EPS 71c, consensus 70c »

Net interest income was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 26

    Apr

  • 03

    May

WK

Workiva

$16.80

-0.05 (-0.30%)

16:24
04/25/17
04/25
16:24
04/25/17
16:24
Hot Stocks
Workiva partners with Fastpath »

Workiva and Fastpath,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    May

UVE

Universal Insurance

$23.35

0.45 (1.97%)

16:24
04/25/17
04/25
16:24
04/25/17
16:24
Earnings
Universal Insurance reports Q1 EPS 86c, consensus 80c »

Book value per common was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

CCI

Crown Castle

$94.27

-0.44 (-0.46%)

16:23
04/25/17
04/25
16:23
04/25/17
16:23
Syndicate
Crown Castle 4.75M share Spot Secondary; price range $93.57-$94.27 »

Barclays, RBC Capital,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 18

    May

TRN

Trinity Industries

16:23
04/25/17
04/25
16:23
04/25/17
16:23
Earnings
Trinity Industries reports Q1 EPS 30c, consensus 30c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 01

    May

  • 09

    May

SPN

Superior Energy

$13.47

0.47 (3.62%)

16:23
04/25/17
04/25
16:23
04/25/17
16:23
Earnings
Superior Energy reports Q1 EPS (59c), consensus (61c) »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 01

    May

  • 01

    May

  • 23

    May

ZIXI

ZixCorp

$5.21

-0.14 (-2.62%)

16:23
04/25/17
04/25
16:23
04/25/17
16:23
Earnings
ZixCorp backs FY17 adjusted EPS view of 28c, consensus 27c »

Raises FY17 revenue view…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 02

    May

  • 03

    May

EW

Edwards Lifesciences

$98.92

0.96 (0.98%)

16:23
04/25/17
04/25
16:23
04/25/17
16:23
Technical Analysis
Edwards Lifesciences spikes higher after results »

In the extended session…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.